{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T13:49:57Z","timestamp":1767275397398,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Alport syndrome (AS) is a genetically heterogeneous disorder resulting from variants in genes coding for the alpha-3\/4\/5 chains of Collagen IV, leading to defective basement membranes in the kidney, cochlea, and eye. The clinical manifestations of AS vary in patients. Cases of childhood AS caused by <jats:italic>COL4A3<\/jats:italic> presenting primarily with nephrotic syndrome (NS) are rarely reported. Here, we report a pediatric case presenting initially with NS attributed to AS caused by <jats:italic>COL4A3<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>An 11-year-old boy presented with hematuria and nephrotic range proteinuria. After excluding secondary causes, primary NS was considered. He was administered with prednisone (60\u2005mg\/day). The patient had not responded to treatment by the end of 4\u2005weeks, so he was diagnosed with steroid-resistant NS. A renal biopsy showed granular and vacuolar degeneration of renal tubular epithelial cells, multifocal foam cell infiltration in the renal interstitium, and immunofluorescence indicated the absence of \u03b13, \u03b14, and \u03b15 expression in the glomerular and tubular basement membrane, while Bowman's capsule expression was normal. Electron microscopy ultrastructural suggested variable basement membrane thickness, and partial tearing and web-like structures. Genetic testing revealed a heterozygous <jats:italic>COL4A3<\/jats:italic> missense mutation c.3210 (exon 37)G&amp;gt;A(NM:000091). These findings are consistent with the diagnosis of AS. Prednisone was gradually tapered and enalapril maleate was initiated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We have described a pediatric case of AS featuring NS as its primary manifestation. It is important to consider AS to be a diagnosis or differential diagnosis in patients who have NS with hematuria or steroid resistance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1518553","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:16:03Z","timestamp":1736316963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Nephrotic syndrome as the primary manifestation of Alport syndrome in a Chinese pediatric patient"],"prefix":"10.3389","volume":"12","author":[{"given":"Yue","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06408-3","article-title":"An unusual case of nephrotic syndrome","volume":"39","author":"Wildes","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.xkme.2020.05.014","article-title":"Alport syndrome classification and management","volume":"2","author":"Warady","year":"2020","journal-title":"Kidney Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101941","DOI":"10.1016\/j.trim.2023.101941","article-title":"A case report and literature study on Alport syndrome featuring nephrotic syndrome as its primary manifestation","volume":"81","author":"Deng","year":"2023","journal-title":"Transpl Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3760\/cma.j.cn112137-20230203-00161","article-title":"[Expert consensus on the diagnosis and treatment of Alport syndrome (version 2023)]","volume":"103","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678633","DOI":"10.3389\/fped.2021.678633","article-title":"Clinical features and familial mutations in an autosomal-inherited Alport syndrome patient with the presentation of nephrotic syndrome","volume":"9","author":"Wang","year":"2021","journal-title":"Front Pediatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.4103\/1319-2442.289453","article-title":"A rare cause of nephrotic syndrome","volume":"31","author":"Thomas","year":"2020","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3760\/cma.j.issn.0578-1310.2015.09.015","article-title":"[A case of autosomal recessive Alport syndrome with nephrotic syndrome as initial symptom]","volume":"53","author":"Ding","year":"2015","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jcm8020178","article-title":"Features of autosomal recessive Alport syndrome: a systematic review","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ajkd.2003.08.002","article-title":"Autosomal recessive Alport\u2019s syndrome and benign familial hematuria are collagen type IV diseases","volume":"42","author":"Vega","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00467-015-3302-4","article-title":"Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy","volume":"31","author":"Weber","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0149241","DOI":"10.1371\/journal.pone.0149241","article-title":"Efficient targeted next generation sequencing-based workflow for differential diagnosis of Alport-related disorders","volume":"11","author":"Kov\u00e1cs","year":"2016","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14399","article-title":"First patient diagnosed with lipoprotein glomerulopathy and Alport syndrome","author":"Yang","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-023-03165-7","article-title":"Alport syndrome misdiagnosed with IgA nephropathy from familial history: a case report and brief review","volume":"24","author":"Rahimzadeh","year":"2023","journal-title":"BMC Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40001-021-00543-5","article-title":"Co-existence of Alport syndrome and C3 glomerulonephritis in a proband with family history","volume":"26","author":"Ding","year":"2021","journal-title":"Eur J Med Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"sfae119","DOI":"10.1093\/ckj\/sfae119","article-title":"Genome editing and kidney health","volume":"17","author":"Tavakolidakhrabadi","year":"2024","journal-title":"Clin Kidney J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00467-021-05040-9","article-title":"Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome","volume":"36","author":"Zhang","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0135648","DOI":"10.1371\/journal.pone.0135648","article-title":"The accumulation of VEGFA in the glomerular basement membrane and its relationship with podocyte injury and proteinuria in Alport syndrome","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000513777","article-title":"Study design and baseline characteristics of the CARDINAL trial: a phase 3 study of bardoxolone methyl in patients with Alport syndrome","volume":"52","author":"Chertow","year":"2021","journal-title":"Am J Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1089\/hum.2018.205","article-title":"Dysregulated expression of microRNA-21 and disease-related genes in human patients and in a mouse model of Alport syndrome","volume":"30","author":"Guo","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/CS20191276","article-title":"SGLT2 inhibitors\u2014a potential treatment for Alport syndrome","volume":"134","author":"Mabillard","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-020-0315-4","article-title":"The current and future landscape of dialysis","volume":"16","author":"Himmelfarb","year":"2020","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1518553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T06:16:07Z","timestamp":1736316967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1518553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":25,"alternative-id":["10.3389\/fped.2024.1518553"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1518553","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1518553"}}